<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678791</url>
  </required_header>
  <id_info>
    <org_study_id>M2020411</org_study_id>
    <nct_id>NCT04678791</nct_id>
  </id_info>
  <brief_title>Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma</brief_title>
  <official_title>To Investigate the Efficacy and Safety of Nimotuzumab Combined With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Local Advanced Cervical Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of nimotuzumab combined with concurrent&#xD;
      chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of local advanced&#xD;
      cervical squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study adopts a multi-center, randomized controlled, open-label clinical trial design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year progression-free survival (PFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The rate of patient without progress disease in 3 years after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival (OS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The rate of patient alive in 3 years after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR)</measure>
    <time_frame>3 months later after treatment</time_frame>
    <description>Percentage of subjects in this group who achieve complete response by imaging assessment from the end of treatment to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 months later after treatment</time_frame>
    <description>The percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute adverse events</measure>
    <time_frame>up to 3 months complete treatment</time_frame>
    <description>Number and grade of participants with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Cervical Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab+ chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive cisplatin and undergo external-beam radiation and brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.</description>
    <arm_group_label>Nimotuzumab+ chemoradiotherapy</arm_group_label>
    <other_name>EGFR monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Nimotuzumab+ chemoradiotherapy</arm_group_label>
    <other_name>Cisplatin injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External-beam radiation</intervention_name>
    <description>Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Nimotuzumab+ chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 ~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Nimotuzumab+ chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75 years old;&#xD;
&#xD;
          2. Histologically diagnosed primary cervical squamous cell carcinoma, with clinical stage&#xD;
             IB3-IVA (FIGO 2018);&#xD;
&#xD;
          3. At least one measurable lesion according to RECIST 1.1;&#xD;
&#xD;
          4. Absence of severe hematopoietic dysfunction and heart, lung, liver, kidney dysfunction&#xD;
             and immunodeficiency, laboratory test results meet the following criteria:&#xD;
&#xD;
             Hemoglobin ≥ 90 g/L; Absolute neutrophil count ≥ 2 × 109/L or white blood cell count ≥&#xD;
             4.0 × 109/L; Platelet count ≥ 100 × 109/L; Aspartate aminotransferase (AST) ≤ 2.5 ×&#xD;
             ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN Total bilirubin ≤ 1.5 × ULN; Serum&#xD;
             creatinine ≤ 1.0 × ULN;&#xD;
&#xD;
          5. ECOG score 0-2 points;&#xD;
&#xD;
          6. Expected survival ≥ 3 months;&#xD;
&#xD;
          7. Women of childbearing potential must have a negative serum or urine HCG within 72&#xD;
             hours prior to enrollment (postmenopausal women must have been amenorrheic for at&#xD;
             least 12 months to be considered of non-childbearing potential. A pregnancy test is&#xD;
             not required for women who have demonstrated tubal ligation);&#xD;
&#xD;
          8. No intrauterine device;&#xD;
&#xD;
          9. Women of childbearing potential who are willing to take medically recognized&#xD;
             contraceptive measures during the trial;&#xD;
&#xD;
         10. Compliance is good and informed consent is voluntarily signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cervical adenocarcinoma and rare pathological types of malignant tumors;&#xD;
&#xD;
          2. Previous surgery for cervical cancer, pelvic radiation therapy, systemic chemotherapy,&#xD;
             tumor targeted therapy, immunotherapy;&#xD;
&#xD;
          3. Ureteral obstruction, inability to place ureteral stent or pyelostomy;&#xD;
&#xD;
          4. Pregnant or lactating women;&#xD;
&#xD;
          5. Patients with rectovaginal fistula/vaginovesical fistula/uncontrolled vaginal bleeding&#xD;
             or at risk of fistula;&#xD;
&#xD;
          6. Human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          7. Active hepatitis B (the quantitative detection result of HBV DNA exceeds the lower&#xD;
             limit of detection), or HCV infection (the quantitative detection result of HCV RNA&#xD;
             exceeds the lower limit of detection);&#xD;
&#xD;
          8. Patients have a serious underlying condition that precludes safe administration of&#xD;
             trial treatment. Including but not limited to active infection requiring systemic drug&#xD;
             therapy: decompensated heart failure (NYHA Class III and IV), unstable angina&#xD;
             pectoris, acute myocardial infarction within 3 months prior to enrollment;&#xD;
&#xD;
          9. Patients with a history of other malignant tumors (except cured cutaneous basal cell&#xD;
             carcinoma);&#xD;
&#xD;
         10. Patients with Crohn's disease and ulcerative colitis;&#xD;
&#xD;
         11. Patients who are participating in other clinical trials or have stopped clinical&#xD;
             trials for less than 4 weeks;&#xD;
&#xD;
         12. Patients with known hypersensitivity to Nimotuzumab or its components;&#xD;
&#xD;
         13. Patients with contraindications to cisplatin;&#xD;
&#xD;
         14. Patients with neurological or psychiatric disorders affecting cognitive ability;&#xD;
&#xD;
         15. Patients whose lesions cannot be treated with intracavitary radiotherapy as assessed&#xD;
             by the investigator;&#xD;
&#xD;
         16. Other reasons that, in the judgment of the investigator, would make the patient&#xD;
             inappropriate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University 3rd Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijng</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Junjie Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

